跳到正文
原文
HHS· @HHSGov · X·· 6 天前精选AI 评分40
AI 导读

美国FDA肿瘤卓越中心与退伍军人事务部研究机构(@VAResearch)签署新MOU,合作方向包括剂量优化和真实世界证据等。首个项目已在推进,研究人员正在研究DPYD基因变异如何影响结直肠癌退伍军人患者体内化疗药5-氟尿嘧啶(5-FU)的代谢。

推荐理由

FDA肿瘤卓越中心与退伍军人事务部研究机构签署MOU,读者可了解双方在剂量优化和真实世界证据上的合作方向。

正文

America’s veterans deserve the highest standard of cancer care.

@US_FDA and @DeptVetAffairs are joining forces to advance cancer research, improve treatments, and deliver better outcomes.

Under @POTUS, we’re honoring those who served — not just on Veterans Day, but every day. 🇺🇸

引用U.S. FDA@FDA
This #VeteransDay, FDA's Oncology Center of Excellence & @VAResearch are teaming up with a new MOU. It supports collaboration on dose optimization, real-world evidence, & more — all to better serve #Veterans and protect public health. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-center-excellence-and-department-veterans-affairs The first project under this MOU is already underway! Researchers are studying how variants in the DPYD gene affect the body's processing of the chemotherapy drug 5-fluorouracil (5-FU) in veterans with colorectal cancer.
在 X 查看被引用的帖子

来源:HHS · x.com